BLPH logo

Bellerophon Therapeutics (BLPH) Cash From Financing

Annual CFF

-$40.00 K
-$40.00 K-100.00%

December 31, 2022

Summary

Performance

1-Year Change

-100%

3-Year Change

-100.65%

5-Year Change

-100.14%

15-Year Change

-100.14%

BLPH Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$87.38 M
BLPH annual cash flow from financing activities is currently -100.05% below its historical high of $87.38 million

3-Year Low

-$40.00 K
BLPH annual cash flow from financing activities is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2022
BLPH previous annual earnings announcement was published on Dec 31, 2022

Next Annual Earnings Report Date

N/A
BLPH next annual earnings announcement has not yet been scheduled

OtherBLPHcash flowmetrics:

Annual CFI

-
BLPH annual cash flow from investing activities value is unknown

Annual CFO

-$17.77 M
BLPH annual cash flow from operations is -$17.77 million

Annual FCF

-$17.77 M
BLPH annual free cash flow is -$17.77 million

Annual CAPEX

-
BLPH annual capital expenditures value is unknown

Quarterly CFF

$0.00
-$26.00 K-100.00%

September 30, 2023

Summary

Performance

3-Month Change

0%

1-Year Change

0%

3-Year Change

0%

5-Year Change

-100%

BLPH Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$89.25 M
BLPH quarterly cash flow from financing activities is currently -100.00% below its historical high of $89.25 million

3-Year Low

-$40.00 K

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2023
BLPH previous earnings announcement was published on Sep 30, 2023

Next Quarterly Earnings Report Date

N/A
BLPH next earnings announcement has not yet been scheduled

OtherBLPHcash flowmetrics:

Quarterly CFI

$140.00 K
BLPH quarterly cash flow from investing activities is $140.00 thousand

Quarterly CFO

-$6.33 M
BLPH quarterly cash flow from operations is -$6.33 million

Quarterly FCF

-$6.33 M
BLPH quarterly free cash flow is -$6.33 million

Quarterly CAPEX

-
BLPH quarterly capital expenditures value is unknown

TTM CFF

$4.97 M
$0.000.00%

September 30, 2023

Summary

Performance

3-Month Change

0%

1-Year Change

+100%

3-Year Change

+100%

5-Year Change

+100%

BLPH TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$89.25 M
BLPH TTM cash flow from financing activities is currently -94.43% below its historical high of $89.25 million

3-Year Low

-$40.00 K

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2023
BLPH previous earnings announcement was published on Sep 30, 2023

Next Quarterly Earnings Report Date

N/A
BLPH next earnings announcement has not yet been scheduled

OtherBLPHcash flowmetrics:

TTM CFI

$140.00 K
BLPH TTM cash flow from investing activities is $140.00 thousand

TTM CFO

-$12.34 M
BLPH TTM cash flow from operations is -$12.34 million

TTM FCF

-$12.34 M
BLPH TTM free cash flow is -$12.34 million

TTM CAPEX

-
BLPH TTM capital expenditures value is unknown

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

BLPH Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-100.0%0.0%+100.0%
3 y3 years-100.7%0.0%+100.0%
5 y5 years-100.1%-100.0%+100.0%

BLPH Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year<-9999.0%at low-100.0%<-9999.0%at high-100.8%
5 y5-year-100.1%at low-100.0%<-9999.0%-91.4%-100.8%
alltimeall time-100.0%at low-100.0%<-9999.0%-94.4%-118.1%

Bellerophon Therapeutics Cash From Financing History

DateAnnualQuarterlyTTM
Sep 2023
-
$0.00(-100.0%)
$4.97 M(0.0%)
Jun 2023
-
$26.00 K(-99.5%)
$4.97 M(+0.5%)
Mar 2023
-
$4.98 M(<-9900.0%)
$4.94 M(<-9900.0%)
Dec 2022
-$40.00 K(<-9900.0%)
-$40.00 K(<-9900.0%)
-$40.00 K(<-9900.0%)
Sep 2022
-
$0.00(0.0%)
$0.00(0.0%)
Jun 2022
-
$0.00(0.0%)
$0.00(0.0%)
Mar 2022
-
$0.00(-100.0%)
$0.00(-100.0%)
Dec 2021
$0.00(-100.0%)
-
-
Dec 2020
$57.57 M(+833.5%)
-$9000.00(-97.9%)
$57.57 M(+0.1%)
Sep 2020
-
-$421.00 K(-100.8%)
$57.51 M(-0.7%)
Jun 2020
-
$54.94 M(+1697.2%)
$57.93 M(+1932.6%)
Mar 2020
-
$3.06 M(-4530.4%)
$2.85 M(-53.8%)
Dec 2019
$6.17 M(+3615.1%)
-$69.00 K(<-9900.0%)
$6.17 M(-1.1%)
Sep 2019
-
$0.00(-100.0%)
$6.24 M(-0.4%)
Jun 2019
-
-$138.00 K(-102.2%)
$6.26 M(-4.7%)
Mar 2019
-
$6.37 M(>+9900.0%)
$6.57 M(+3856.6%)
Dec 2018
$166.00 K
$0.00(-100.0%)
$166.00 K(-86.9%)
Sep 2018
-
$25.00 K(-85.2%)
$1.27 M(-94.9%)
Jun 2018
-
$169.00 K(-703.6%)
$24.91 M(-9.3%)
DateAnnualQuarterlyTTM
Mar 2018
-
-$28.00 K(-102.5%)
$27.47 M(-1.1%)
Dec 2017
$27.78 M(+110.4%)
$1.10 M(-95.3%)
$27.78 M(-26.8%)
Sep 2017
-
$23.66 M(+766.8%)
$37.97 M(+143.8%)
Jun 2017
-
$2.73 M(+857.9%)
$15.57 M(+15.4%)
Mar 2017
-
$285.00 K(-97.5%)
$13.49 M(+2.2%)
Dec 2016
$13.21 M(-75.5%)
$11.29 M(+789.4%)
$13.21 M(+542.7%)
Sep 2016
-
$1.27 M(+94.9%)
$2.06 M(+161.5%)
Jun 2016
-
$651.00 K(>+9900.0%)
$786.00 K(-187.6%)
Mar 2016
-
$0.00(-100.0%)
-$897.00 K(-101.7%)
Dec 2015
$54.01 M(-38.2%)
$135.00 K(>+9900.0%)
$54.01 M(+2.9%)
Sep 2015
-
$0.00(-100.0%)
$52.48 M(-1.3%)
Jun 2015
-
-$1.03 M(-101.9%)
$53.17 M(+0.3%)
Mar 2015
-
$54.91 M(-4025.0%)
$53.04 M(-39.3%)
Dec 2014
$87.38 M(+50.8%)
-$1.40 M(-302.2%)
$87.38 M(-1.6%)
Sep 2014
-
$692.00 K(-159.2%)
$88.78 M(+0.8%)
Jun 2014
-
-$1.17 M(-101.3%)
$88.08 M(-1.3%)
Mar 2014
-
$89.25 M
$89.25 M
Dec 2013
$57.96 M(+46.0%)
-
-
Dec 2012
$39.70 M
-
-

FAQ

  • What is Bellerophon Therapeutics annual cash flow from financing activities?
  • What is the all time high annual CFF for Bellerophon Therapeutics?
  • What is Bellerophon Therapeutics annual CFF year-on-year change?
  • What is Bellerophon Therapeutics quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for Bellerophon Therapeutics?
  • What is Bellerophon Therapeutics quarterly CFF year-on-year change?
  • What is Bellerophon Therapeutics TTM cash flow from financing activities?
  • What is the all time high TTM CFF for Bellerophon Therapeutics?
  • What is Bellerophon Therapeutics TTM CFF year-on-year change?

What is Bellerophon Therapeutics annual cash flow from financing activities?

The current annual CFF of BLPH is -$40.00 K

What is the all time high annual CFF for Bellerophon Therapeutics?

Bellerophon Therapeutics all-time high annual cash flow from financing activities is $87.38 M

What is Bellerophon Therapeutics annual CFF year-on-year change?

Over the past year, BLPH annual cash flow from financing activities has changed by -$40.00 K (-100.00%)

What is Bellerophon Therapeutics quarterly cash flow from financing activities?

The current quarterly CFF of BLPH is $0.00

What is the all time high quarterly CFF for Bellerophon Therapeutics?

Bellerophon Therapeutics all-time high quarterly cash flow from financing activities is $89.25 M

What is Bellerophon Therapeutics quarterly CFF year-on-year change?

Over the past year, BLPH quarterly cash flow from financing activities has changed by $0.00 (0.00%)

What is Bellerophon Therapeutics TTM cash flow from financing activities?

The current TTM CFF of BLPH is $4.97 M

What is the all time high TTM CFF for Bellerophon Therapeutics?

Bellerophon Therapeutics all-time high TTM cash flow from financing activities is $89.25 M

What is Bellerophon Therapeutics TTM CFF year-on-year change?

Over the past year, BLPH TTM cash flow from financing activities has changed by +$4.97 M (+100.00%)